

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Shawn C. Black, et al. :

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Herewith : Group Art Unit: To be assigned

TITLE: PHOSPHODIESTERASE 9 INHIBITION AS :
TREATMENT FOR OBESITY-RELATED
CONDITIONS

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: April 27th, 2006

Respectfully submitted,


Deborah A. Martin
Attorney for Applicant(s)
Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC25667A				SERIAL NO. To be assigned							
									APPLICANT Shawn C. Black, et al.											
									FILING DATE Herewith								GROUP To be assigned			
U.S. PATENT DOCUMENTS																				
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE							
	US	6	2	5	5	4	5	6	7/3/01	Fisher, et al.	C07K	1/00								
	US	2003	0	1	6	6	6	62	9/4/03	Fryburg, et al.	A61K	31/5377								
	US	2004	0	2	2	0	1	86	11/4/04	Bell, et al.	A61K	31/53								
FOREIGN PATENT DOCUMENTS																				
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION							
													YES	NO						
	WO	0	0	4	7	2	0	6	8/17/00	International	A61K	31/40								
	WO	0	3	0	2	8	7	30	7/10/03	International	A61K	31/505								
	WO	0	3	0	3	7	4	32	5/8/03	International	A61P	3/06								
	WO	0	3	0	6	1	6	38	7/31/03	International	A61K	31/00								
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																				
		Dousa, T., <i>Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney</i> , <u>Kidney International</u> , Vol. 55: 29-62, 1999																		
		Fisher, D., et al., <i>Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase</i> , <u>The Journal of Biological Chemistry</u> , Vol. 273(25): 1559-15564, 1998																		
		Soderling, S., et al., <i>Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases</i> , <u>The Journal of Biological Chemistry</u> , Vol. 273(25): 15553-15558, 1998																		
<table style="width: 100%;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> </table>																	EXAMINER	DATE CONSIDERED		
EXAMINER	DATE CONSIDERED																			
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																				

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. EV770921858 US